TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18454510

Group type: EXPERIMENTAL
Intervention: Ribavirin 800 mg/day plus peginterferon alfa‐2a 180 mug/week
Number of subjects: 141

Group type: COMPARATOR
Intervention: Ribavirin 400 mg/day plus peginterferon alfa‐2a 180 mug/week
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ribavirin 800 mg/day (group A)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Ribavirin 400 mg/day (group B)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study: 16290907

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b 1.5 microg/kg subcutaneously once weekly plus ribavirin 800-1400 mg/day for 24 weeks
Number of subjects: 235

Group type: COMPARATOR
Intervention: Historical control (Manns et al., Lancet 2001)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Patients with undetectable serum HCV-RNA at treatment week 4
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (historical)
Number of subjects: 235
Study: 12603706

Group type: EXPERIMENTAL
Intervention: Prophylactic group (educational package + mite allergen‐impermeable mattress encasings)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Prophylactic group
Number of subjects: 696
Study: 10957824

Group type: EXPERIMENTAL
Intervention: Suppression instructions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonsuppression instructions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Punishment and worry thought control strategies
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Distraction cognitive strategy
Number of subjects: 40
Study: 8788532

Group type: EXPERIMENTAL
Intervention: 5‐HT1a‐receptor agonist ipsapirone (10 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2058830

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study: 6403706

Group type: EXPERIMENTAL
Intervention: 0.5 mg norethindrone + 35 micrograms ethinyl estradiol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ethynodiol diacetate and norethindrone
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing preparation
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Norethindrone or ethynodiol diacetate
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Levonorgestrel preparation
Number of subjects: 4
Study: 3948638

Group type: EXPERIMENTAL
Intervention: Patient education modules (up to seven modules) including didactic instruction, skill exercises, and behavioral modification techniques.
Number of subjects: 532

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 532
Study: 29842843

Group type: EXPERIMENTAL
Intervention: Self-Selected (SS) recovery
Number of subjects: 14

Group type: COMPARATOR
Intervention: Externally Regulated (ER) recovery
Number of subjects: 14
Study: 28718569

Group type: EXPERIMENTAL
Intervention: 10% potassium hydroxide aqueous solution applied daily to the lesions twice daily for 6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen, applied weekly for 6 weeks
Number of subjects: 120
Study: 23818159

Group type: EXPERIMENTAL
Intervention: Multimodal intervention including letters, automated phone calls, prompts, and a mailed Fecal Immunochemical Testing (FIT) Kit
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 366
Study: 22634906

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (500 mg/5 cc) three times a week for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study: 20361911

Group type: EXPERIMENTAL
Intervention: Assertive community treatment (ACT) as part of integrated care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study: 18652921

Group type: EXPERIMENTAL
Intervention: Fetal movement counting (testing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No testing (control)
Number of subjects: 0
Study: 15932822

Group type: EXPERIMENTAL
Intervention: Supracervical hysterectomy (SCH)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 135
Study: 12891538

Group type: EXPERIMENTAL
Intervention: Screening and eradication for Helicobacter pylori (Hp)
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Hp-eradicated participants
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Overall health care consultation
Number of subjects: 20000
Study: 10472698

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg bodyweight ketamine racemate before skin incision and 10 micrograms/kg/min ketamine infusion until peritoneum closure, followed by sodium chloride 0.9% as placebo after final skin suture.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebos before skin incision and intraoperatively, followed by 0.5 mg/kg bodyweight ketamine after last skin suture.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebos at all three points of time.
Number of subjects: 39
Study: 8557385

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus metronidazole
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cefotaxime plus gentamicin plus metronidazole
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 79
Study: 1932765

Group type: EXPERIMENTAL
Intervention: buflomedil (400 mg intravenous perfusion for 4 hours daily for 7 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: buflomedil
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 7044160

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 165

Group type: COMPARATOR
Intervention: Co-trimoxazole (high daily dosage regimens)
Number of subjects: 165
Study: 30717614

Group type: EXPERIMENTAL
Intervention: Alcohol (0.4 g/kg)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Combined data (Alcohol vs. Placebo)
Number of subjects: 302
Study: 27428397

Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) for nonattendees of reduced-preparation CTC
Number of subjects: 16087

Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) for nonattendees of full-preparation CTC
Number of subjects: 16087

Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) for nonattendees of OC
Number of subjects: 16087
Study: 25210009

Group type: EXPERIMENTAL
Intervention: Computerized decision support system
Number of subjects: 21230

Group type: COMPARATOR
Intervention: Standard software alone
Number of subjects: 21230
Study: 25201518

Group type: EXPERIMENTAL
Intervention: Single morning dose of mitotane
Number of subjects: 10

Group type: COMPARATOR
Intervention: No morning dose of mitotane
Number of subjects: 10
Study: 22379738

Group type: EXPERIMENTAL
Intervention: Vitamin E 350 mg daily for 1 month (n = 5)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo for 1 month (n = 4)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 14
Study: 20569710

Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone/10 microg ethinyl estradiol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 17699816

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 286

Group type: COMPARATOR
Intervention: No further therapy (control group)
Number of subjects: 286
Study: 17038829

Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02
Number of subjects: 2

Group type: COMPARATOR
Intervention: YF‐VAX (licensed yellow fever 17D vaccine)
Number of subjects: 2
Study: 11417280

Group type: EXPERIMENTAL
Intervention: Four-layer bandages (4LB)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Short-stretch bandages (SSB)
Number of subjects: 112
Study: 9241098

Group type: EXPERIMENTAL
Intervention: BIS 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BIS 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8106952

Group type: EXPERIMENTAL
Intervention: Periodontal dressing with 0.2% chlorhexidine mouthwash (10 ml for 1 minute twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No periodontal dressing with 0.2% chlorhexidine mouthwash (10 ml for 1 minute twice daily)
Number of subjects: 24
Study: 3307404

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Weight reduction, exercise, diet, and glipizide therapy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Behaviorally oriented nutrition-exercise program
Number of subjects: 15

Group type: COMPARATOR
Intervention: Insulin (baseline)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Eucaloric diet
Number of subjects: 15
Study: 31382815

Group type: EXPERIMENTAL
Intervention: Improved PVP
Number of subjects: 44

Group type: COMPARATOR
Intervention: Traditional PVP
Number of subjects: 44
Study: 28786358

Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 0
Study: 26521182

Group type: EXPERIMENTAL
Intervention: 8-week intervention combining muscle resistance, aerobic and inspiratory pressure load exercises
Number of subjects: 48
Study: 23890855

Group type: EXPERIMENTAL
Intervention: Tibetan diet
Number of subjects: 524

Group type: COMPARATOR
Intervention: Usual care (Western diet)
Number of subjects: 524
Study: 21786577

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 30
Study: 19423999

Group type: EXPERIMENTAL
Intervention: Transdermal microdose 17beta-estradiol (0.014 mg/d)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Oral raloxifene (60 mg/d)
Number of subjects: 500
Study: 16919005

Group type: EXPERIMENTAL
Intervention: First-line bosentan treatment
Number of subjects: 358
Study: 14726165

Group type: EXPERIMENTAL
Intervention: Allergen plus diesel exhaust particles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allergen alone
Number of subjects: 0
Study: 11360697

Group type: EXPERIMENTAL
Intervention: Adult hearing screening with audiometric testing at 0.5, 1, 2, 3, and 4 kHz; advice given if average hearing loss exceeded 20 dBHL; noise avoidance emphasized if thresholds exceeded 25 dBHL bilaterally at 4 kHz.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 9406128

Group type: EXPERIMENTAL
Intervention: Nonprotein calorie group: dextrose and lipid intake equal to measured energy expenditure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total calorie group: dextrose, lipid, and protein intake equal to measured energy expenditure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypocaloric group: dextrose and lipid intake equal to 50% of measured energy expenditure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (nonprotein and total calorie)
Number of subjects: 0
Study: 8484675

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB) with bupivacaine alone (Ba)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Suprascapular nerve block (SSNB) with bupivacaine plus methylprednisolone (Ba + P)
Number of subjects: 29
Study: 3319646

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg o.d.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg o.d.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg o.d.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 28605819

Group type: EXPERIMENTAL
Intervention: Frameless fiducial-less brain biopsy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Frame-based stereotactic biopsy
Number of subjects: 56
Study: 27091318

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) 150 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: NaCl (control) 24 mg/kg
Number of subjects: 24
Study: 25219389

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Algorithm-based pharmacological treatment
Number of subjects: 73
Study: 22523120

Group type: EXPERIMENTAL
Intervention: Text message-based smoking cessation intervention
Number of subjects: 2915
Study: 21205234

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus acetylsalicylic acid
Number of subjects: 4318

Group type: COMPARATOR
Intervention: Placebo plus acetylsalicylic acid
Number of subjects: 4318
Study: 18274692

Group type: EXPERIMENTAL
Intervention: Guideline dissemination
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Guideline dissemination plus educational session
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Guideline dissemination, educational session, plus individualised treatment advice
Number of subjects: 362
Study: 16864749

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 18002

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 18002
Study: 14583366

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 8768
Study: 11360070

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg daily for 7 days (treated partners)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (untreated partners)
Number of subjects: 144
Study: 8083713

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate at 150 mg/m2/d
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (various doses: 50, 75, 100, 125, 150, 175, and 200 mg/m2/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate and etoposide
Number of subjects: 36
Study: 2587982

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol spray
Number of subjects: 0
Study: 1234503

Group type: EXPERIMENTAL
Intervention: Clobazam (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide hydrochloride (20 mg)
Number of subjects: 0
Study: 31422111

Group type: EXPERIMENTAL
Intervention: CA125-guided diuretic treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study: 30844137

Group type: EXPERIMENTAL
Intervention: Poor relationship consensus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Relationship cohesion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Relationship satisfaction
Number of subjects: 60
Study: 28358246

Group type: EXPERIMENTAL
Intervention: Direct renin inhibition (DRI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Angiotensin receptor blocker (ARB)
Number of subjects: 24
Study: 25933495

Group type: EXPERIMENTAL
Intervention: High-fat meal (HF; 46 g fat, 1210 kcal)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low-fat meal (LF; 15 g fat, 1214 kcal)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-energy meal (HF or LF)
Number of subjects: 17
Study: 24468780

Group type: EXPERIMENTAL
Intervention: 1.0 mg of eravacycline/kg intravenously every 12 h for a total of seven doses over 4 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eravacycline concentrations in ELF at 2, 4, 6, and 12 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eravacycline concentrations in AM at 2, 4, 6, and 12 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison of eravacycline concentrations in ELF and AM to plasma
Number of subjects: 20
Study: 22999793

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Insulin stimulation
Number of subjects: 30
Study: 19651060

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (EST)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 211
Study: 17489325

Group type: EXPERIMENTAL
Intervention: Triptorelin (monthly injection, group 1; n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Surgical castration (pulpectomy, group 2; n = 40)
Number of subjects: 80
Study: 15278236

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly sensitive diagnostic tools (RT-PCR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Operative or conservative therapies in sentinel node-positive patients
Number of subjects: 0
Study: 11309436

Group type: EXPERIMENTAL
Intervention: Optimized-treatment arm (40 mg mitomycin C with pharmacokinetic manipulations and urine alkalinization)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Standard-treatment arm (20 mg mitomycin C without pharmacokinetic manipulations or urine alkalinization)
Number of subjects: 230
Study: 9674777

Group type: EXPERIMENTAL
Intervention: High vagus nerve stimulation
Number of subjects: 196

Group type: COMPARATOR
Intervention: Low vagus nerve stimulation
Number of subjects: 196
Study: 7489167

Group type: EXPERIMENTAL
Intervention: Suprapubic catheterization
Number of subjects: 57

Group type: COMPARATOR
Intervention: Urethral catheterization
Number of subjects: 57
Study: 2023746

Group type: EXPERIMENTAL
Intervention: Aminocaproic acid (Amicar) 50 mg/kg every 4 hours for 5 days (max 30 g daily)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Prednisone 40 mg daily (adjusted for weight) in two divided doses
Number of subjects: 112
Study: 6452796

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline-N-oxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine-N-oxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomifensine (large doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine (75 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine (150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine (225 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine (300 mg)
Number of subjects: 0
Study: 30850099

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 98

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 98
Study: 28848225

Group type: EXPERIMENTAL
Intervention: Magnesium oxide supplementation (up to a maximum of 3 times 450 mg daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No supplements (Control)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 52
Study: 24580722

Group type: EXPERIMENTAL
Intervention: Strong identification with employer
Number of subjects: 100

Group type: COMPARATOR
Intervention: Single and multiple organizational sources
Number of subjects: 100
Study: 23398554

Group type: EXPERIMENTAL
Intervention: Stapler A (CPH32; Frankenman International Ltd, Hong Kong, China)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stapler B (PPH03; Ethicon Endo‐Surgery, Spreitenbach, Switzerland)
Number of subjects: 50
Study: 21444144

Group type: EXPERIMENTAL
Intervention: Manually operated hand‐powered mechanical resuscitation device (MRD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard single rescuer basic life support (BLS)
Number of subjects: 80
Study: 19323865

Group type: EXPERIMENTAL
Intervention: Mobile phone-operated weight-loss programme (n=62)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No intervention (Control group, n=63)
Number of subjects: 125
Study: 17452151

Group type: EXPERIMENTAL
Intervention: Rescue percutaneous coronary intervention (rPCI)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 307
Study: 15291660

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 179
Study: 11133624

Group type: EXPERIMENTAL
Intervention: 0.078 microg/mL sufentanil
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 0.156 microg/mL sufentanil
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 0.312 microg/mL sufentanil
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 0.468 microg/mL sufentanil
Number of subjects: 328

Group type: COMPARATOR
Intervention: No sufentanil
Number of subjects: 328
Study: 9439023

Group type: EXPERIMENTAL
Intervention: Grunge rock music
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Designer music
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: New Age music
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 144
Study: 8021737

Group type: EXPERIMENTAL
Intervention: Oral etoposide (VP-16) at 50 mg/m2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral etoposide (VP-16) at 60 mg/m2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral etoposide (VP-16) at 75 mg/m2
Number of subjects: 20
Study: 2915763

Group type: EXPERIMENTAL
Intervention: L-carnitine therapy (1 g i.v.) at the end of dialysis for 1 month, followed by L-carnitine added to the dialysate (2 g in group 1, 4 g in group 2) for 3 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: L-carnitine added to the dialysate (2 g in group 1, 4 g in group 2)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravenous administration of L-carnitine (2 g)
Number of subjects: 22
Study: 31968346

Group type: EXPERIMENTAL
Intervention: MCO HD
Number of subjects: 89
Study: 30169840

Group type: EXPERIMENTAL
Intervention: High-frequency spinal cord stimulation (HF-SCS) at 10 kHz
Number of subjects: 5
Study: 28526046

Group type: EXPERIMENTAL
Intervention: Plain balloon angioplasty with or without bail-out bare metal stenting
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon angioplasty with or without bail-out bare metal stenting
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Primary stenting with drug-eluting stents
Number of subjects: 861
Study: 25623382

Group type: EXPERIMENTAL
Intervention: Diode laser treatment (L group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Open flap debridement (C group)
Number of subjects: 19
Study: 23010700

Group type: EXPERIMENTAL
Intervention: 10% sucralfate ointment
Number of subjects: 48